Droxidopa
- Generic Name
- Droxidopa
- Brand Names
- Northera
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO5
- CAS Number
- 23651-95-8
- Unique Ingredient Identifier
- J7A92W69L7
- Background
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopa...
- Indication
For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainti...
- Associated Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Associated Therapies
- -
Droxidopa in Treating Patients With Neurogenic Hypotension
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-18
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Registration Number
- NCT00004478
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.